| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
| Targets |
Aminoglycoside
Micronomicin targets the bacterial ribosome, specifically the 30S ribosomal subunit, where it binds to the A-site of 16S rRNA. This binding interferes with the initiation of protein synthesis and causes misreading of the genetic code, leading to the production of non-functional or toxic proteins. The compound's bactericidal activity is concentration-dependent and is more effective against aerobic Gram-negative bacteria. |
|---|---|
| ln Vitro |
Micronomicin exhibits strong antibacterial properties; it effectively combats Staphylococcus aureus FDA 209 P, exhibiting minimal inhibitory values of 0.01 μg/ml. Additionally, it is anti-Escherichia coli St. M. The minimal inhibitory values were 0.75 μg/ml, 0.3 μg/ml, 0.03 μg/ml, and 0.03 μg/ml for 589, Baker 2, F 14-BK, and R5/W677. Additionally, it exhibits activity against strains of Lebsiella pneumoniae and Pseudomonas aeruginosa (MICs = 0.03-17.5 μg/ml)[1].
Micronomicin exhibits broad-spectrum antibacterial activity against various Gram-positive and Gram-negative bacteria. It is active against many strains of Enterobacteriaceae, Pseudomonas aeruginosa, Staphylococcus aureus, and other clinically relevant pathogens. The compound's in vitro activity is similar to that of gentamicin. Minimum inhibitory concentrations (MICs) vary depending on the bacterial species and strain. |
| ln Vivo |
Micronomicin sulfate has an intravenous acute LD50 of 93 mg/kg in mice and is very effective against a variety of bacterial infections in mice[1]. Subacute toxicity studies involve the intravenous injection of micronomicin sulfate at a dose of 4-100 mg/kg over a 30-day period. Ataxia and renal problems cause the wistar rats (10 out of 30 animals) to die at the 100 mg/kg dose. Renal histopathological abnormalities primarily manifest at dosages beyond 25 mg/kg [3].
In vivo, micromonicin has been used clinically for the treatment of various bacterial infections. It demonstrates efficacy in treating respiratory tract infections, urinary tract infections, skin and soft tissue infections, and other bacterial infections. The compound's pharmacokinetic and pharmacodynamic properties support its use as a therapeutic antibiotic. However, like other aminoglycosides, it requires careful dosing to minimize toxicity. |
| Enzyme Assay |
The antibacterial activity of micromonicin is assessed using standard broth microdilution or agar dilution methods according to CLSI or EUCAST guidelines. Bacteria are cultured in appropriate media and exposed to varying concentrations of micromonicin. The minimum inhibitory concentration (MIC) is determined as the lowest concentration that inhibits visible bacterial growth. Time-kill assays are performed to assess the bactericidal activity of the compound.
|
| Cell Assay |
Cellular assays for micromonicin typically employ bacterial cultures rather than mammalian cells. Bacteria are cultured in liquid media in 96-well plates and treated with varying concentrations of micromonicin. Bacterial growth is monitored by measuring optical density at 600 nm (OD600) or by colony counting. The minimum bactericidal concentration (MBC) is determined by subculturing wells with no visible growth onto agar plates.
|
| Animal Protocol |
Animal/Disease Models: Wistar rats[3]
Doses: 4, 10, 25, 63 mg/kg and 100 mg/kg Route of Administration: intravenous (iv)injection; 30 days Experimental Results: Led to death of rat at 100 mg/kg. In vivo efficacy of micromonicin is evaluated in animal models of infection, such as mouse thigh infection models or systemic infection models. Infected animals are treated with micromonicin via various routes of administration (intravenous, intramuscular, subcutaneous) at different doses. Bacterial burden in tissues or blood is measured by colony counting. Survival rates are monitored. The compound's efficacy is compared with other aminoglycosides. |
| ADME/Pharmacokinetics |
Micronomicin sulfate has molecular formula C20H41N5O7·H2SO4 (approximate) and molecular weight around 561.65 (free base). It has CAS number 66803-19-8. The compound is soluble in water and is typically supplied as a powder. It should be stored at room temperature or as recommended by the manufacturer. The compound is a research-grade antibiotic.
|
| Toxicity/Toxicokinetics |
Micronomicin, like other aminoglycosides, is associated with nephrotoxicity and ototoxicity (both vestibular and cochlear). Risk factors include high doses, prolonged treatment, and pre-existing renal impairment. The compound should be used with caution and under medical supervision. Monitoring of serum drug levels and renal function is recommended during therapy. The compound should be handled with appropriate laboratory safety precautions.
|
| References |
|
| Additional Infomation |
Micronomicin sulfate is an aminoglycoside sulfate that functions similarly to Micronomicin.
Micronomicin sulfate is also known as gentamicin C2b sulfate, antibiotic XK-62-2 sulfate, and sagamicin sulfate. It is an aminoglycoside antibiotic produced by Micromonospora sagamiensis. Micronomicin is structurally related to gentamicin and has been used clinically for the treatment of various bacterial infections. The compound has broad-spectrum antibacterial activity against Gram-positive and Gram-negative bacteria. |
| Molecular Formula |
C20H41N5O7.XH2SO4
|
|---|---|
| Molecular Weight |
561.64732
|
| Exact Mass |
561.268
|
| CAS # |
66803-19-8
|
| Related CAS # |
Micronomicin;52093-21-7
|
| PubChem CID |
171808
|
| Appearance |
White to yellow solid powder
|
| Density |
1.32g/cm3
|
| Boiling Point |
667.2ºC at 760mmHg
|
| Flash Point |
357.3ºC
|
| Hydrogen Bond Donor Count |
10
|
| Hydrogen Bond Acceptor Count |
16
|
| Rotatable Bond Count |
7
|
| Heavy Atom Count |
37
|
| Complexity |
688
|
| Defined Atom Stereocenter Count |
12
|
| SMILES |
C[C@@]1(CO[C@@H]([C@@H]([C@H]1NC)O)O[C@H]2[C@@H](C[C@@H]([C@H]([C@@H]2O)O[C@@H]3[C@@H](CC[C@H](O3)CNC)N)N)N)O.OS(=O)(=O)O
|
| InChi Key |
MQDGQSCLOYLSEK-SCFBDNQUSA-N
|
| InChi Code |
InChI=1S/C20H41N5O7.H2O4S/c1-20(28)8-29-19(14(27)17(20)25-3)32-16-12(23)6-11(22)15(13(16)26)31-18-10(21)5-4-9(30-18)7-24-2;1-5(2,3)4/h9-19,24-28H,4-8,21-23H2,1-3H3;(H2,1,2,3,4)/t9-,10+,11-,12+,13-,14+,15+,16-,17+,18+,19+,20-;/m0./s1
|
| Chemical Name |
(2R,3R,4R,5R)-2-[(1S,2S,3R,4S,6R)-4,6-diamino-3-[(2R,3R,6S)-3-amino-6-(methylaminomethyl)oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol;sulfuric acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : 50 mg/mL
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 100 mg/mL (Infinity mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication.
(Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.7805 mL | 8.9023 mL | 17.8047 mL | |
| 5 mM | 0.3561 mL | 1.7805 mL | 3.5609 mL | |
| 10 mM | 0.1780 mL | 0.8902 mL | 1.7805 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
